A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes

Sarah Joseph, Killian Quinn, Aldona Greenwood, Alethea V. Cope, Paul F. McKay, Peter J. Hayes, Jakub T. Kopycinski, Jill Gilmour, Aleisha N. Miller, Christof Geldmacher, Yuka Nadai, Mohamed I.M. Ahmed, David C. Montefiori, Len Dally, George Bouliotis, David J.M. Lewis, Roger Tatoud, Ralf Wagner, Mariano Esteban, Robin J. Shattock & 2 others Sheena McCormack, Jonathan Weber

Research output: Research - peer-reviewArticle

  • 1 Citations

Abstract

There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included =grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders, p = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in > 80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.

LanguageEnglish (US)
Article number149
JournalFrontiers in Immunology
Volume8
Issue numberFEB
DOIs
StatePublished - Feb 22 2017

Fingerprint

env Gene Products
AIDS Vaccines
Immunization
DNA
GP 140
T-Lymphocytes
Combined Vaccines
Vaccination
Vaccines
Immunoglobulin G
Lipids
Safety
Antibodies
Immunodominant Epitopes
Antibody Specificity
Neutralizing Antibodies
Antibody Formation
Volunteers
Plasmids
anti-IgG

Keywords

  • DNA
  • Envelope protein
  • HIV vaccine
  • MVA
  • Phase I trial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes. / Joseph, Sarah; Quinn, Killian; Greenwood, Aldona; Cope, Alethea V.; McKay, Paul F.; Hayes, Peter J.; Kopycinski, Jakub T.; Gilmour, Jill; Miller, Aleisha N.; Geldmacher, Christof; Nadai, Yuka; Ahmed, Mohamed I.M.; Montefiori, David C.; Dally, Len; Bouliotis, George; Lewis, David J.M.; Tatoud, Roger; Wagner, Ralf; Esteban, Mariano; Shattock, Robin J.; McCormack, Sheena; Weber, Jonathan.

In: Frontiers in Immunology, Vol. 8, No. FEB, 149, 22.02.2017.

Research output: Research - peer-reviewArticle

Joseph, S, Quinn, K, Greenwood, A, Cope, AV, McKay, PF, Hayes, PJ, Kopycinski, JT, Gilmour, J, Miller, AN, Geldmacher, C, Nadai, Y, Ahmed, MIM, Montefiori, DC, Dally, L, Bouliotis, G, Lewis, DJM, Tatoud, R, Wagner, R, Esteban, M, Shattock, RJ, McCormack, S & Weber, J 2017, 'A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes' Frontiers in Immunology, vol 8, no. FEB, 149. DOI: 10.3389/fimmu.2017.00149
Joseph, Sarah ; Quinn, Killian ; Greenwood, Aldona ; Cope, Alethea V. ; McKay, Paul F. ; Hayes, Peter J. ; Kopycinski, Jakub T. ; Gilmour, Jill ; Miller, Aleisha N. ; Geldmacher, Christof ; Nadai, Yuka ; Ahmed, Mohamed I.M. ; Montefiori, David C. ; Dally, Len ; Bouliotis, George ; Lewis, David J.M. ; Tatoud, Roger ; Wagner, Ralf ; Esteban, Mariano ; Shattock, Robin J. ; McCormack, Sheena ; Weber, Jonathan. / A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes. In: Frontiers in Immunology. 2017 ; Vol. 8, No. FEB.
@article{18b826285b3543969b571c8e97bcbb07,
title = "A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes",
abstract = "There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included =grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders, p = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in > 80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.",
keywords = "DNA, Envelope protein, HIV vaccine, MVA, Phase I trial",
author = "Sarah Joseph and Killian Quinn and Aldona Greenwood and Cope, {Alethea V.} and McKay, {Paul F.} and Hayes, {Peter J.} and Kopycinski, {Jakub T.} and Jill Gilmour and Miller, {Aleisha N.} and Christof Geldmacher and Yuka Nadai and Ahmed, {Mohamed I.M.} and Montefiori, {David C.} and Len Dally and George Bouliotis and Lewis, {David J.M.} and Roger Tatoud and Ralf Wagner and Mariano Esteban and Shattock, {Robin J.} and Sheena McCormack and Jonathan Weber",
year = "2017",
month = "2",
doi = "10.3389/fimmu.2017.00149",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes

AU - Joseph,Sarah

AU - Quinn,Killian

AU - Greenwood,Aldona

AU - Cope,Alethea V.

AU - McKay,Paul F.

AU - Hayes,Peter J.

AU - Kopycinski,Jakub T.

AU - Gilmour,Jill

AU - Miller,Aleisha N.

AU - Geldmacher,Christof

AU - Nadai,Yuka

AU - Ahmed,Mohamed I.M.

AU - Montefiori,David C.

AU - Dally,Len

AU - Bouliotis,George

AU - Lewis,David J.M.

AU - Tatoud,Roger

AU - Wagner,Ralf

AU - Esteban,Mariano

AU - Shattock,Robin J.

AU - McCormack,Sheena

AU - Weber,Jonathan

PY - 2017/2/22

Y1 - 2017/2/22

N2 - There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included =grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders, p = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in > 80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.

AB - There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included =grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders, p = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in > 80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.

KW - DNA

KW - Envelope protein

KW - HIV vaccine

KW - MVA

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=85014352086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014352086&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00149

DO - 10.3389/fimmu.2017.00149

M3 - Article

VL - 8

JO - Frontiers in Immunology

T2 - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - FEB

M1 - 149

ER -